Evolent Health (EVH) Reports Q4: Everything You Need To Know Ahead Of Earnings
Healthcare solutions company Evolent Health (NYSE:EVH) will be announcing its earnings results this Tuesday after market close. Here’s what to expect.
Evolent Health exceeded analysts’ revenue expectations last quarter, reporting revenues of $479.5 million, although this represented a 22.8% decline year on year. It was a challenging quarter for the company, with a significant miss in EPS estimates and EBITDA guidance for the upcoming quarter falling short of analysts’ expectations.
Is Evolent Health a Buy or Sell?
This quarter, the market anticipates Evolent Health’s revenue to decline by 27.5% year on year, reversing the 16.3% increase recorded during the same quarter last year.
Over the last 30 days, analysts covering the company have generally reconfirmed their estimates, suggesting they expect the business to maintain its course heading into earnings. It is worth noting that Evolent Health has missed Wall Street’s revenue estimates on multiple occasions over the past two years.
Comparing Evolent Health to its peers in the healthcare technology sector, some companies have already reported their Q4 results, which provide insight into expectations. Omnicell saw year-on-year revenue growth of 2.3%, meeting analysts’ expectations, while Tandem Diabetes reported a 15% increase in revenues, exceeding estimates by 4.9%. Following these results, Omnicell’s stock traded down 20.6%, whereas Tandem Diabetes surged 32.7%.
Debates surrounding the economy’s health and the effects of potential tariffs and corporate tax cuts have introduced considerable uncertainty throughout 2025. While some healthcare technology stocks have performed well in this volatile landscape, the sector has generally underperformed, with share prices down 3.4% on average over the past month. During this period, Evolent Health has dropped 24.8% and is heading into earnings with an average analyst price target of $8.50, compared to its current share price of $2.79.
At Inside Ticker, we recognize the potential of thematic investing. Successful growth stories from companies like Microsoft (MSFT), Alphabet (GOOG), Coca-Cola (KO), and Monster Beverage (MNST) have been driven by significant megatrends. In that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.